BioNTech SE (BNTX) — Financial statements
Income statement, balance sheet, and cash flow for BioNTech SE — annual and quarterly history with growth and margin analysis.
| Metric (EUR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2,757↑0.2% | 2,751↓28.0% | 3,819↓77.9% | 17,311↓8.8% | 18,977 | |
| Cost of Revenue | 616↑13.9% | 541↓9.8% | 600↓80.0% | 2,995↑2.9% | 2,912 | |
| Gross Profit | 2,140↓3.2% | 2,210↓31.4% | 3,219↓77.5% | 14,316↓10.9% | 16,065 | |
| Operating Expenses | ||||||
| R&D Expenses | 2,022↓10.3% | 2,254↑26.4% | 1,783↑16.0% | 1,537↑61.9% | 949 | |
| General & Administrative Expenses | 588↑10.8% | 531↑7.3% | 495↑2.8% | 482↑74.0% | 277 | |
| Selling & Marketing Expenses | 110↑62.0% | 68↑8.3% | 63↑5.4% | 60↑18.1% | 50 | |
| SG&A Expenses | 698↑16.6% | 599↑7.4% | 558↑3.0% | 541↑65.4% | 327 | |
| Other Expenses | 44↓93.4% | 671↑256.9% | 188↑146.4% | -405↑18.1% | -495 | |
| Operating Expenses | 2,764↓21.6% | 3,524↑39.4% | 2,529↑51.2% | 1,673↑114.1% | 781 | |
| Total Costs & Expenses | 3,380↓16.8% | 4,065↑29.9% | 3,129↓33.0% | 4,668↑26.4% | 3,693 | |
| Operating Results | ||||||
| Operating Income | -624↑52.5% | -1,314↓290.4% | 690↓94.5% | 12,643↓17.3% | 15,284 | |
| Depreciation & Amortization | 368↑23.4% | 298↑62.5% | 183↑48.7% | 123↑64.0% | 75 | |
| EBITDA | -256↑30.2% | -367↓126.7% | 1,377↓89.5% | 13,096↓12.7% | 15,002 | |
| EBIT | -624↑6.2% | -665↓155.7% | 1,194↓90.8% | 12,973↓13.1% | 14,927 | |
| Interest & Other Income | ||||||
| Net Interest Income | 239↑1912.8% | -13↓103.8% | 344↑989.1% | 32↑875.9% | -4 | |
| Interest Income | 252 | 0.00↓100.0% | 351↑641.7% | 47↑2929.2% | 2 | |
| Interest Expense | 14↑3.6% | 13↑69.6% | 8↓50.9% | 16↑181.1% | 6 | |
| Non-Operating Income | 0.00↑100.0% | -649↓28.9% | -504↓52.5% | -330↓192.6% | 357 | |
| Other Income / Expenses | -385↓160.6% | 637↑28.4% | 496↑59.2% | 311↑231.2% | -237 | |
| Income Before Tax | -1,009↓48.9% | -678↓157.1% | 1,186↓90.8% | 12,954↓13.9% | 15,046 | |
| Income Tax Expense | 82↑760.8% | -12↓104.8% | 256↓92.7% | 3,520↓26.0% | 4,754 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -1,091↓64.0% | -665↓171.5% | 930↓90.1% | 9,434↓8.3% | 10,293 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -1,091↓64.0% | -665↓171.5% | 930↓90.1% | 9,434↓8.3% | 10,293 | |
| Bottom-Line Net Income | -1,091↓64.0% | -665↓171.5% | 930↓90.1% | 9,434↓8.3% | 10,293 | |
| EPS (Basic) | -4.51↓62.8% | -2.77↓171.6% | 3.87↓89.8% | 38.08↓13.2% | 43.87 | |
| EPS (Diluted) | -4.51↓62.8% | -2.77↓172.3% | 3.83↓89.7% | 37.09↓10.0% | 41.21 | |
| Weighted Average Shares | 242↑0.5% | 240↓0.1% | 241↓1.1% | 243↓0.3% | 244 | |
| Weighted Average Diluted Shares | 242↑0.5% | 240↓0.9% | 243↓2.8% | 250↓3.8% | 260 | |
* All figures in Millions of EUR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.